pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$DYNDyne Therapeutics, Inc.

$DYN16.94+7.76%
Waltham, MA, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Preclinical: 2Phase 2: 2
2Preclinical2Phase 2
Phase 2
zeleciment basivarsen
Myotonic Dystrophy
Phase 2
zeleciment rostudirsen
Duchenne Muscular Dystrophy
Preclinical
DYNE-302
Facioscapulohumeral Muscular Dystrophy (FSHD)
Preclinical
FORCEM-23D
Duchenne Muscular Dystrophy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1recruitingn=150
  • phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1active not recruitingn=127
  • phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skippingactive not recruitingn=86
🐶 Hiring Signal
No open roles indexed yet — view Dyne Therapeutics, Inc. jobs →

News

  • Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
    Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
    biospace · 1d ago
  • PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
    Mean splicing correction for PepGen’s PGN-EDODM1 was 46.5% at week 13, compared to under 30% for competitors like Dyne Therapeutics, Novartis and Ionis Pharmaceuticals.
    biospace · 7d ago
  • Biopharma hiring hotspots: States, disciplines where demand is highest
    As biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other loca…
    biospace · 2mo ago
  • Novartis RNA drug falls short in rare muscle disease study
    The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
    biopharma_dive · 2mo ago
  • Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
    While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity…
    biospace · 2mo ago
  • Capricor CEO won’t rule out legal action against FDA after negative adcomm
    After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…
    biospace · 3mo ago
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    biopharma_dive · 4mo ago
identifiers
ticker
$DYN
SEC CIK
0001818794
country
US
source
sec_tickers
top tags
Duchenne Muscular Dystrophy2
mentioned in
7news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 40m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?